PDF(Pubmed)
Abstract：
UNASSIGNED: Patients with inoperable extrabronchial or endobronchial tumors who are not candidates for curative radiotherapy have dire prognoses with no effective long-term treatment options. To reveal that our computer-optimized interstitial photodynamic therapy (I-PDT) is safe and potentially effective in the treatment of patients with inoperable extra or endobronchial malignancies inducing central airway obstructions.
UNASSIGNED: High-spatial resolution computer simulations were used to personalize the light dose rate and dose for each tumor. Endobronchial ultrasound with a transbronchial needle was used to place the optical fibers within the tumor according to an individualized plan. The primary and secondary end points were safety and overall survival, respectively. An exploratory end point evaluated changes in immune markers.
UNASSIGNED: Eight patients received I-PDT with planning, and five of these received additional external beam PDT. Two additional patients received external beam PDT. The treatment was declared safe. Three of 10 patients are alive at 26.3, 12, and 8.3 months, respectively, after I-PDT. The treatments were able to deliver a prescribed light dose rate and dose to 87% to 100% and 18% to 92% of the tumor volumes, respectively. A marked increase in the proportion of monocytic myeloid-derived suppressor cells expressing programmed death-ligand 1 was measured in four of seven patients.
UNASSIGNED: Image-guided light dosimetry for I-PDT with linear endobronchial ultrasound transbronchial needle is safe and potentially beneficial in increasing overall survival of patients. I-PDT has a positive effect on the immune response including an increase in the proportion of programmed death-ligand 1-expressing monocytic myeloid-derived suppressor cells.
UNASSIGNED: High-spatial resolution computer simulations were used to personalize the light dose rate and dose for each tumor. Endobronchial ultrasound with a transbronchial needle was used to place the optical fibers within the tumor according to an individualized plan. The primary and secondary end points were safety and overall survival, respectively. An exploratory end point evaluated changes in immune markers.
UNASSIGNED: Eight patients received I-PDT with planning, and five of these received additional external beam PDT. Two additional patients received external beam PDT. The treatment was declared safe. Three of 10 patients are alive at 26.3, 12, and 8.3 months, respectively, after I-PDT. The treatments were able to deliver a prescribed light dose rate and dose to 87% to 100% and 18% to 92% of the tumor volumes, respectively. A marked increase in the proportion of monocytic myeloid-derived suppressor cells expressing programmed death-ligand 1 was measured in four of seven patients.
UNASSIGNED: Image-guided light dosimetry for I-PDT with linear endobronchial ultrasound transbronchial needle is safe and potentially beneficial in increasing overall survival of patients. I-PDT has a positive effect on the immune response including an increase in the proportion of programmed death-ligand 1-expressing monocytic myeloid-derived suppressor cells.
摘要：
UNASSIGNED：无法手术的支气管外或支气管内肿瘤患者不适合根治性放疗，其预后不佳，没有有效的长期治疗选择。揭示我们的计算机优化的间质光动力疗法（I-PDT）在治疗无法手术的支气管外恶性肿瘤或支气管内恶性肿瘤引起中央气道阻塞的患者中是安全且潜在有效的。
UNASSIGNED：使用高空间分辨率计算机模拟来个性化每个肿瘤的光剂量率和剂量。根据个性化计划，使用带支气管针的支气管内超声将光纤放置在肿瘤内。主要和次要终点是安全性和总生存期,分别。探索性终点评估免疫标志物的变化。
未经授权：8名患者在计划时接受了I-PDT，其中五个接收了额外的外部波束PDT。另外两名患者接受了外部束PDT。该治疗被宣布为安全的。10名患者中有3名在26.3、12和8.3个月时存活，分别,在I-PDT之后.治疗能够提供规定的光剂量率和剂量87％至100％和18％至92％的肿瘤体积，分别。在7名患者中的4名中，测量到表达程序性死亡配体1的单核细胞衍生的抑制细胞的比例显着增加。
UNASSIGNED：使用线性支气管内超声针对I-PDT进行图像引导光剂量测定是安全的，并且可能有益于提高患者的总体生存率。I-PDT对免疫反应具有积极作用，包括增加表达程序性死亡配体1的单核细胞髓源性抑制细胞的比例。
UNASSIGNED：使用高空间分辨率计算机模拟来个性化每个肿瘤的光剂量率和剂量。根据个性化计划，使用带支气管针的支气管内超声将光纤放置在肿瘤内。主要和次要终点是安全性和总生存期,分别。探索性终点评估免疫标志物的变化。
未经授权：8名患者在计划时接受了I-PDT，其中五个接收了额外的外部波束PDT。另外两名患者接受了外部束PDT。该治疗被宣布为安全的。10名患者中有3名在26.3、12和8.3个月时存活，分别,在I-PDT之后.治疗能够提供规定的光剂量率和剂量87％至100％和18％至92％的肿瘤体积，分别。在7名患者中的4名中，测量到表达程序性死亡配体1的单核细胞衍生的抑制细胞的比例显着增加。
UNASSIGNED：使用线性支气管内超声针对I-PDT进行图像引导光剂量测定是安全的，并且可能有益于提高患者的总体生存率。I-PDT对免疫反应具有积极作用，包括增加表达程序性死亡配体1的单核细胞髓源性抑制细胞的比例。
